ARS Pharmaceuticals Inc’s recently made public that its Director Shawver Laura unloaded Company’s shares for reported $0.62 million on Feb 03 ’25. In the deal valued at $12.31 per share,50,000 shares were sold. As a result of this transaction, Shawver Laura now holds 210,346 shares worth roughly $2.14 million.
Then, Shawver Laura bought 50,000 shares, generating $615,565 in total proceeds.
Before that, Shawver Laura sold 50,000 shares. ARS Pharmaceuticals Inc shares valued at $555,065 were divested by the Director at a price of $11.10 per share. As a result of the transaction, Shawver Laura now holds 210,346 shares, worth roughly $2.14 million.
Oppenheimer initiated its ARS Pharmaceuticals Inc [SPRY] rating to an Outperform in a research note published on February 10, 2025; the price target was $40. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid August with a ‘”an Overweight”‘ rating. Raymond James also remained covering SPRY and has increased its forecast on August 13, 2024 with a “Strong buy” recommendation from previously “an Outperform” rating. Leerink Partners maintained its rating on August 12, 2024. It rated SPRY as “an Outperform”.
Price Performance Review of SPRY
On Monday, ARS Pharmaceuticals Inc [NASDAQ:SPRY] saw its stock fall -2.86% to $10.18. Over the last five days, the stock has lost -6.00%. ARS Pharmaceuticals Inc shares have fallen nearly -3.51% since the year began. Nevertheless, the stocks have risen 12.86% over the past one year. While a 52-week high of $18.51 was reached on 01/27/25, a 52-week low of $7.55 was recorded on 03/03/25. SMA at 50 days reached $11.87, while 200 days put it at $12.10.
Levels Of Support And Resistance For SPRY Stock
The 24-hour chart illustrates a support level at 9.91, which if violated will result in even more drops to 9.65. On the upside, there is a resistance level at 10.54. A further resistance level may holdings at 10.91. The Relative Strength Index (RSI) on the 14-day chart is 31.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.88, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.97%. Stochastics %K at 9.95% indicates the stock is a buying.
The most recent change occurred on July 25, 2024 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $18 price target.
